Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

COVID19 has not yet reached its peak in Brazil, says GlobalData

Recently, Brazil has steadily climbed the chart of the top 10 countries with the highest total of COVID19 cases, now ranking number two just behind the US. The epidemiology forecast shows that Brazil has not reached peak and it is likely that the outbreak will continue to worsen there, says GlobalData, a leading data and […]
Read more

Remdesivir faces challenges from vaccines, says GlobalData

While Gilead Sciences’ remdesivir has been declared the new standard of care for COVID-19 despite some mixed trial results, it will continue to face challenges from vaccines in the pipeline, says GlobalData, a leading data and analytics company. Once a vaccine is developed, the demand for remdesivir to treat COVID-19 patients will decline. Johanna Swanson, […]
Read more

Liquidia’s pocket-sized PAH treatment LIQ-861 likely to be favored by patients

If the development of Liquidia Technologies’ LIQ-861 dry powder inhaled formulation of treprostinil, indicated for the treatment of pulmonary arterial hypertension (PAH) is successful, the drug will likely be favored by patients and physicians as it will likely increase patient compliance, says GlobalData, a leading data and analytics company. Kajal Jaddoo, MSc, Associate Healthcare Analyst […]
Read more

COVID-19 is driving innovations in healthcare staff training process

COVID-19–accelerated adoption of emerging technologies will revolutionize the frontline staff education and training process and become a new normal once the COVID-19 crisis ends, says GlobalData, a leading data and analytics company. Urte Jakimaviciute, MSc, Senior Director of Market Research, commented: “The shortage of trained medical staff has obliged governments to consider alternative ways of […]
Read more

Gilead’s remdesivir gets MHRA green light, but only targets select group of COVID-19 patients

GlobalData anticipates that Gilead’s remdesivir will target a select severity group of COVID-19 patients, and it remains questionable as to how treatment with the drug will be initiated and optimized.  Angad Lotay MPharm, Infectious Diseases Analyst at GlobalData, states: “Gilead’s remdesivir was trialled in a number of patients with varying severities, however, it was noted […]
Read more

Clinical trials are adapting to a patient safety concerns over COVID-19

When clinical trials that were delayed since the beginning of the COVID-19 pandemic resume, it is highly probable that potential trial subjects will have a heightened sense of anxiety regarding COVID-19 and therefore may have reservations about participating, says GlobalData, a leading data and analytics company. Mohamed Abukar, MSc, Clinical Trials Analyst at GlobalData, comments: “In […]
Read more

Operation Warp Speed’s finalists for COVID-19 vaccine are announced, but vaccines need to be accessible globally to control the pandemic

Following the news that the US Government’s ‘Operation Warp Speed’ picked AstraZeneca, Johnson & Johnson, Merck, Moderna, and Pfizer as finalists for COVID-19 vaccine funding; Philipp Rosenbaum, PhD, Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offers his view: “Operation Warp Speed’s goal to support the production of 300 million vaccine doses […]
Read more

MERS vaccine shows promise for COVID-19 vaccine development

A recent Phase I clinical trial performed at the University Medical Center Hamburg-Eppendorf for a Middle East respiratory syndrome (MERS) vaccine has produced positive results that give hope that a vaccine candidate for COVID-19 can be developed using the same technique. This provides evidence that a coronavirus vaccine can be made that is both safe and triggers […]
Read more

Interferon-lambda has potential to reduce transmission of COVID-19

The spread of the COVID-19 can be slowed by the use of interferon-lambda, which has the ability to inhibit replication of COVID-19 in the lungs and gastrointestinal tracts. This reduced replication of the virus lessens the amount of viral shedding and can reduce the chances of viral transmission, says GlobalData a leading data analytics company. […]
Read more

Clinical trials disrupted by COVID-19 are slowly resuming

The COVID-19 pandemic has been disrupting clinical trials globally, but as countries reopen, these trials are now resuming. As of 28th May, over 130 COVID-19 disrupted clinical trials were resuming, with the US leading the way in the number of trials resumed by site locations at 69% of the resumed trials, says GlobalData, a leading data […]
Read more

Local production of APIs in India for COVID-19 repurposed drugs likely to offer competitive advantage, says GlobalData

The local production of the active pharmaceutical ingredients (API) for some of the key COVID-19 repurposed drugs including remdesivir, favipiravir and hydroxychloroquine (HCQ) is likely to offer a competitive advantage for the formulations manufactured in India in terms of supply and price, says GlobalData, a leading data and analytics company. According to GlobalData’s COVID-19 Executive […]
Read more

Some injectable sedatives used for ventilated COVID-19 patients are experiencing shortages, finds GlobalData

The ongoing COVID-19 pandemic has increased the demand for drugs used to sedate the mechanically ventilated COVID-19 patients and has resulted in shortages for some of these drugs, specifically propofol and dexmedetomidine hydrochloride, says GlobalData, a leading data and analytics company. As the COVID-19 pandemic continues to spread, about 20% of hospitalized COVID-19 patients need […]
Read more

COVID-19 to temporarily setback blockchain implementation in global pharmaceutical supply chains

Even though blockchain stands out as a potential solution to improve pharmaceutical supply chains, COVID-19 may become a hindrance rather than a trigger in the technology’s future implementation and uptake, says GlobalData, a leading data and analytics company. Urte Jakimaviciute, MSc, Senior Director of Market Research at GlobalData, comments: “A blockchain-based distributed ledger can provide […]
Read more

Anti-TNF therapies could treat patients with COVID-19-related acute respiratory distress, says GlobalData

Remicade (infliximab) and Humira (adalimumab) are the established anti-tumor necrosis factor (TNF) therapies that have been shown to decrease inflammation in diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). As these anti-TNF therapies reduce inflammation, they could treat COVID-19 patients with acute respiratory distress (ARDS), says GlobalData, a leading data and analytics […]
Read more
1 … 89 90 91 92 93 … 108